Revolution Medicines Future Growth
Future criteria checks 2/6
Revolution Medicines is forecast to grow earnings and revenue by 9.6% and 61.4% per annum respectively. EPS is expected to grow by 17.5% per annum. Return on equity is forecast to be -96.9% in 3 years.
Key information
9.6%
Earnings growth rate
17.5%
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | 61.4% |
Future return on equity | -96.9% |
Analyst coverage | Good |
Last updated | 02 May 2024 |
Recent future growth updates
Recent updates
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 11We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Mar 31Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Dec 16What Does The Future Hold For Revolution Medicines, Inc. (NASDAQ:RVMD)? These Analysts Have Been Cutting Their Estimates
Aug 17Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans
Aug 03Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 28 | -577 | -485 | -480 | 8 |
12/31/2025 | 4 | -562 | -478 | -479 | 12 |
12/31/2024 | 5 | -516 | -435 | -442 | 13 |
12/31/2023 | 12 | -436 | -358 | -351 | N/A |
9/30/2023 | 26 | -331 | -300 | -292 | N/A |
6/30/2023 | 30 | -296 | -252 | -243 | N/A |
3/31/2023 | 35 | -259 | -242 | -232 | N/A |
12/31/2022 | 35 | -249 | -235 | -224 | N/A |
9/30/2022 | 30 | -245 | -211 | -202 | N/A |
6/30/2022 | 27 | -224 | -193 | -187 | N/A |
3/31/2022 | 27 | -208 | -170 | -165 | N/A |
12/31/2021 | 29 | -187 | -154 | -147 | N/A |
9/30/2021 | 29 | -169 | -139 | -133 | N/A |
6/30/2021 | 40 | -143 | -130 | -123 | N/A |
3/31/2021 | 42 | -126 | -115 | -109 | N/A |
12/31/2020 | 43 | -110 | -103 | -100 | N/A |
9/30/2020 | 46 | -95 | -89 | -87 | N/A |
6/30/2020 | 46 | -85 | -76 | -74 | N/A |
3/31/2020 | 48 | -71 | -62 | -65 | N/A |
12/31/2019 | 50 | -62 | -46 | -50 | N/A |
9/30/2019 | 48 | -57 | -46 | -50 | N/A |
12/31/2018 | 20 | -49 | 0 | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RVMD's revenue (61.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: RVMD's revenue (61.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RVMD is forecast to be unprofitable in 3 years.